




The relative strengths and weaknesses of Lyell Immunopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lyell Immunopharma Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 90% points. The greatest weakness of Lyell Immunopharma Inc is the variable Research and Development, reducing the Economic Capital Ratio by 47% points.

The company's Economic Capital Ratio, given in the ranking table, is 248%, being 19% points above the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	260,939
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	49,412
Liabilities, Non-Current	42,438
Other Assets	44,342
Other Compr. Net Income	-49
Other Expenses	-702
Other Liabilities	0
Other Net Income	-5,044
Other Revenues	36
Property and Equipment	34,771
Research and Development	225,007
Selling, General and Administrative Expense	45,135

Output Variable	Value in 1000 USD
Assets	340,052
Liabilities	91,850
Expenses	269,440
Revenues	36
Stockholders Equity	248,202
Net Income	-274,448
Comprehensive Net Income	-274,472
BaseVar	353,236
ECR before Limited Liability	123%
Economic Capital Ratio	248%